Ariceum Therapeutics GmbH has raised a further €22.75 million from a venture capital syndicate to advance its radiopharmaceutical products for the diagnosis and treatment of cancer. The new funding complements an earlier Series A financing round of €25 million, bringing the total amount secured up to €47.75 million. The financing was co-led by new investors Andera Partners and Earlybird Venture Capital, with participation from the existing investor Pureos Bioventures.
